“Shift Toward Precision Neuropharmacology and Behavioral Symptom Targeting”
• A key trend in the global autism drug market is the development of precision medicines targeting specific behavioral symptoms such as irritability, hyperactivity, and social withdrawal.
• There is a growing preference for atypical antipsychotics, stimulants, and selective serotonin reuptake inhibitors (SSRIs), often used in combination for symptom-specific relief.
• For example, risperidone and aripiprazole are widely prescribed and have shown efficacy in managing irritability associated with autism.
• Novel delivery systems, including transdermal patches and long-acting injectables, are being developed to improve compliance in pediatric populations.
• The rising prevalence of ASD and growing research on its neurobiological basis are increasing demand for innovative drug-based interventions.
